Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 25 or more amino acid residues in defined sequence
Reexamination Certificate
2008-09-02
2008-09-02
Bragdon, Kathleen Kerr (Department: 1656)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
25 or more amino acid residues in defined sequence
Reexamination Certificate
active
11677796
ABSTRACT:
The present invention is directed to a composition consisting of a series of novel biologically active 33-mer peptides.
REFERENCES:
patent: 4200435 (1980-04-01), Stroupe et al.
patent: 4977137 (1990-12-01), Nichols et al.
patent: 5006333 (1991-04-01), Saifer et al.
patent: 5198419 (1993-03-01), Ando et al.
patent: 5240909 (1993-08-01), Nitsche
patent: 5304633 (1994-04-01), Tomita et al.
patent: 5317084 (1994-05-01), Tomita et al.
patent: 5322286 (1994-06-01), Frost
patent: 5322836 (1994-06-01), Tomita et al.
patent: 5457093 (1995-10-01), Cini et al.
patent: 5466669 (1995-11-01), Konig et al.
patent: 5571691 (1996-11-01), Conneely et al.
patent: 5571697 (1996-11-01), Conneely et al.
patent: 5571896 (1996-11-01), Conneely et al.
patent: 5576299 (1996-11-01), Ando et al.
patent: 5656591 (1997-08-01), Tomita et al.
patent: 5712247 (1998-01-01), Wu et al.
patent: 5766939 (1998-06-01), Conneely et al.
patent: 5789542 (1998-08-01), McLaughlin et al.
patent: 5834424 (1998-11-01), Valenti et al.
patent: 5849881 (1998-12-01), Conneely et al.
patent: 5849885 (1998-12-01), Nuyens et al.
patent: 5919913 (1999-07-01), Nuyens et al.
patent: 5955316 (1999-09-01), Conneely et al.
patent: 6066469 (2000-05-01), Kruzel et al.
patent: 6080559 (2000-06-01), Conneely et al.
patent: 6100054 (2000-08-01), Conneely et al.
patent: 6111081 (2000-08-01), Conneely et al.
patent: 6228614 (2001-05-01), Conneely et al.
patent: 6277817 (2001-08-01), Kruzel et al.
patent: 6333311 (2001-12-01), Nuijens et al.
patent: 6399570 (2002-06-01), Mann et al.
patent: 6440690 (2002-08-01), Mor et al.
patent: 6455687 (2002-09-01), Kruzel et al.
patent: 6613741 (2003-09-01), Kruzel et al.
patent: 6635447 (2003-10-01), Conneely et al.
patent: 6890902 (2005-05-01), Svendsen et al.
patent: 2002/0016289 (2002-02-01), Conneely
patent: 2002/0064524 (2002-05-01), Cevc
patent: 2002/0072596 (2002-06-01), Ruben et al.
patent: 2002/0107283 (2002-08-01), Codd et al.
patent: 2002/0111295 (2002-08-01), Yajima et al.
patent: 2002/0119928 (2002-08-01), McAnalley
patent: 2003/0039651 (2003-02-01), Olmarker
patent: 2003/0060425 (2003-03-01), Ahlem et al.
patent: 2003/0077641 (2003-04-01), Laskowitz et al.
patent: 2003/0096736 (2003-05-01), Kruzel et al.
patent: 2003/0096763 (2003-05-01), Kruzel et al.
patent: 2003/0105006 (2003-06-01), Mann
patent: 2003/0186854 (2003-10-01), Daffre et al.
patent: 2003/0190303 (2003-10-01), Kimber et al.
patent: 2004/0009895 (2004-01-01), Varadhachary et al.
patent: 2004/0009896 (2004-01-01), Glynn et al.
patent: 2004/0023334 (2004-02-01), Prior
patent: 2004/0082504 (2004-04-01), Varadhachary et al.
patent: 2004/0142037 (2004-07-01), Engelmayer et al.
patent: 2004/0151784 (2004-08-01), Varadhachary et al.
patent: 2004/0152623 (2004-08-01), Varadhachary et al.
patent: 2004/0152624 (2004-08-01), Varadhachary et al.
patent: 2004/0176276 (2004-09-01), Varadhachary et al.
patent: 2005/0004006 (2005-01-01), Engelmayer et al.
patent: 2005/0019342 (2005-01-01), Varadhachary et al.
patent: 2005/0064546 (2005-03-01), Conneely et al.
patent: 2005/0075277 (2005-04-01), Varadhachary et al.
patent: 0426924 (1991-05-01), None
patent: 0478101 (1992-01-01), None
patent: 0730868 (1996-09-01), None
patent: 07233086 (1995-09-01), None
patent: 07316069 (1995-12-01), None
patent: 8165248 (1996-06-01), None
patent: WO-9113982 (1991-09-01), None
patent: WO-9806425 (1998-02-01), None
patent: WO-9844940 (1998-10-01), None
patent: WO-0001730 (2000-01-01), None
patent: WO-0049040 (2000-08-01), None
patent: WO-0172322 (2001-10-01), None
patent: WO-0203910 (2002-01-01), None
patent: WO-0211772 (2002-02-01), None
patent: WO-0241912 (2002-05-01), None
patent: WO-02080891 (2002-10-01), None
patent: WO-02100445 (2002-12-01), None
patent: WO-03061688 (2003-07-01), None
patent: WO-2004024180 (2004-03-01), None
Vogel et al., Towrads a structure-function analysis of bovine lactoferricin and related tryptophan- and arginine-containing peptides, Biochem. cell Biol. 80: 49-63 (2002).
P4663 Poly-L-arginine hydrochloride, CAS No. 26982-20-7 , Sigma-Aldrich Co., 2007, p. 1 of 1.
Amouric et al, “Effect of Lactoferrin on the Growth of a Human Colon Adenocarcinoma Cell Line—Comparison with Transferrin,” In Vitro vol. 20 No. 7, Jul. 1984, pp. 543-548.
Baraniuk et al., “Hypertonic saline nasal provocation stimulates nociceptive nerves, substance P release, and glandular mucous exocytosis in normal humans,”Am. J. Respir. Crit. Care Med., 160: 655-662, 1999.
Barresi et al, “Lactoferrin in Benign Hypertrophy and Carcinomas of the Prostatic Gland,” Virchows Archiv (Pathol Anat) 403; 1984, pp. 59-66.
Bellamy et al., “Antifungal properties of lactoferricin B, a peptide derived from the N-terminal region of bovine lactoferrin,”Lett. Appl. Microbiol., 18: 230-233, 1994.
Bellamy et al., “Identification of the bactericidal domain of lactoferrin,”Biochim. Biophys. Acta, 1121: 130-136, 1992.
Benezra et al., “A synthetic heparin-mimicking polyanionic compound binds to the LDL receptor-related protein and inhibits vascular smooth muscle cell proliferation,”J. Cell. Biochem., 81(1): 114-27, 2001.
Bezault et al, “Human Lactoferrin Inhibits Growth of Solid Tumors and Development of Experimental Metastases in Mice,” Cancer Research 54, May 1, 1994, pp. 2310-2312.
Birgisdottir et al., “Variation in consumption of cow milk proteins and lower incidence of Type 1 diabetes in Iceland vs the other 4 Nordic countries,”DNM, 15(4): 240-245, 2002.
Butte et al, “Milk Composition on Insulin Dependent Diabetic Women,” Journal of Pediatric Gastroenterology and Nutrition vol. 6, 1987, pp. 936-941.
Chan et al, “Autoantibody Formation aster Allogeneic Bone Marrow Transplantation: Correlation with the Reconstitution of CD5+ B Cells and Occurence of Graft-verus-host Disease,” Pathology vol. 29 No. 2, May 1997, pp. 184-188.
Cianflone et al., “Inhibition of lipoprotein lipase induced-cholesterol ester accumulation in human hepatoma HepG2 cells,”Atherosclerosis, 120: 101-114, 1996.
Clare et al., “Bioactive milk peptides: a prospectus,”J. Diary Sci., 83: 1187-1195, 2000.
Clarke et al, “Evaluation of Bovine Lactoferrin as a Topical Therapy for Chemotherapy-induced Mucositis in the Golden Syrian Hamster,” Oral Oncology 35, 1999, pp. 197-202.
Croy et al., “All three LDL receptor homology regions of the LDL receptor-related protein bind multiple ligands,”Biochemistry, 42(44): 13049-13057, 2003.
Cumberbatch et al, “IL-I B-induced Langerhans' cell Migration and TNF-A production in Human Skin: Regulation by Lactoferrin,” Clin Exp. Immunol 132, 2003, pp. 352-359.
Cumberbatch et al, “Regulation of Epidermal Langerhans Cell Migration by Lactoferrin,” Immunology 2000, 100, pp. 21-28.
Damiens et al, “Effects of Human Lactoferrin on NK Cell Cytotoxicity Against Haematopoietic and Epithelial Tumour Cells,” Biochimica et Biophysica Acta 1402, 1998, pp. 277-287.
Damiens et al, “Lactoferrin Inhibits G1 Cyclin-Dependent Kinases During Growth Arrest of Human Breast Carcinoma Cells,” Journal of Cellular Biochemistry 72, 1999, pp. 486-498.
Eckmann, “Mucosal defences against Giardia,”Parasite Immunol., 25(5): 259-270, 2003.
Edde et al, “Lactoferrin Protects Neonatal Rats from Gut-related Systemic Infection,” Am J Physiol Gastrointest Liver Phsyiol 281: G1140-G1150, 2001.
Fujihara et al, “Lactoferrin Protects Against UV-B Irradiation-Induced Corneal Epithelial Damage in Rats,” Cornea 19(2); 2000, pp. 207-211.
Fujita et al, “Down-Regulation of 2-Amino-3, 8-dimethylimidazo [4,5-f] Quinoxaline (MelQx)-induced CYP1A2 Expression is Associated with Bovine Lactoferrin Inhibition of MelQx-induced Liver and Colon Carcinogenesis in Rats,” Jpn. J. Cancer Res. 93, Jun. 2002, pp. 616-625.
Hayashida et al., “Bovine lactoferrin has a nitric oxide-dependent hypotensive effect in rats,”Am. J. Physiol. Regul. Inte
Engelmayer Jose
Glynn Peter
Petrak Karel
Varadhachary Atul
Agennix Inc.
Bragdon Kathleen Kerr
Rooke Agnes B.
LandOfFree
Composition of lactoferrin related peptides and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition of lactoferrin related peptides and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition of lactoferrin related peptides and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3932382